Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03986138 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

A Phase 3 study of Lesion in Body Region, sponsored by Guerbet.

Completed
Registry status
Phase 3
Development phase
324
Enrollment target
20
Study locations

NCT03986138 is a Phase 3 study of Lesion in Body Region that has completed, run by Guerbet. The registered enrollment target is 324 participants. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03986138, a Phase 3 study of Lesion in Body Region, has completed, sponsored by Guerbet.

COMPLETED
Registry status
Phase 3
Development phase
324 participants
Enrollment target
20
Study locations

Study Summary

The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)

Conditions Studied

Interventions

  • DRUG gadopiclenol
  • DRUG Gadobutrol 1 MMOLE/ML Intravenous Solution

Study Locations (20)

Other

  • Acibadem City Clinic Tokuda Hospital Sofia - Sofia
  • CHU - Angers
  • CHU Beaujon - Clichy
  • Hôpital Saint Louis - Paris
  • Klinik für Diagnostische und Interventionelle Radiologie - Aachen
  • Universitätsklinikum Halle - Halle
  • Universitätsklinikum des Saarlandes - Homburg
  • University Hospital Jena - Jena
  • Somogy Megyei Kaposi Mor Oktato Korhaz - Kaposvár
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet - Szolnok
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - Naples
  • Clinical Research Institute S.C. - Estado de México
  • Axis Heilsa S de R.L. de C.V - Althian Clinical Research Management Center - Monterrey

Alabama

  • The University of Alabama at Birmingham - Birmingham

Connecticut

  • UConn Health - University of Connecticut - Farmington

Illinois

  • The University of Chicago Medical Center - Chicago

Massachusetts

  • Boston Medical Center - Boston

Missouri

  • University of Missouri Health System - Columbia

New York

  • Montefiore Medical Center - The Bronx

Texas

  • UT Health San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 324 participants
Start Date 2019-08-27
Est. Completion 2020-12-09
Phase Phase 3

Sponsor

Guerbet

15 total trials

What the Registry Record Tells You About NCT03986138

The ClinicalTrials.gov registry entry for NCT03986138 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lesion in Body Region appearing as the primary indexed condition, and to 2 interventions - of which gadopiclenol is the first listed.

NCT03986138 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Alabama, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03986138 about?

NCT03986138 is a clinical study titled "Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)". The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)

What is the current status of trial NCT03986138?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2019-08-27. Estimated completion is 2020-12-09.

What conditions does trial NCT03986138 study?

This clinical trial studies the following conditions: Lesion in Body Region.

What interventions are being tested in trial NCT03986138?

The interventions under investigation include: gadopiclenol (DRUG), Gadobutrol 1 MMOLE/ML Intravenous Solution (DRUG).

Who is sponsoring clinical trial NCT03986138?

This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03986138 being conducted?

This trial has 20 study locations across Alabama, Connecticut, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.